Filtered By:
Specialty: Drugs & Pharmacology
Infectious Disease: COVID-19
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 161 results found since Jan 2013.
Implications of COVID-19 to Stroke Medicine: An Epidemiological and Pathophysiological Perspective
Curr Vasc Pharmacol. 2022;20(4):333-340. doi: 10.2174/1570161120666220428101337.ABSTRACTThe neurological complications of Coronavirus 2019 (COVID-19) including stroke have been documented in the recent literature. COVID-19-related inflammation is suggested to contribute to both a hypercoagulable state and haemorrhagic transformation, including in younger individuals. COVID-19 is associated with a heightened risk of ischaemic stroke. Haemorrhagic stroke in COVID-19 patients is associated with increased morbidity and mortality. Cerebral venous sinus thrombosis (CVST) accounts for <1% of stroke cases in the general populat...
Source: Current Vascular Pharmacology - November 3, 2022 Category: Drugs & Pharmacology Authors: Alan King Karen M Doyle Source Type: research
Endogenous reparative pluripotent Muse cells with a unique immune privilege system: Hint at a new strategy for controlling acute and chronic inflammation
Multilineage-differentiating stress enduring (Muse) cells, non-tumorigenic endogenous pluripotent stem cells, reside in the bone marrow (BM), peripheral blood, and connective tissue as pluripotent surface marker SSEA-3(+) cells. They express other pluripotent markers, including Nanog, Oct3/4, and Sox2 at moderate levels, differentiate into triploblastic lineages, self-renew at a single cell level, and exhibit anti-inflammatory effects. Cultured mesenchymal stromal cells (MSCs) and fibroblasts contain several percent of SSEA-3(+)-Muse cells. Circulating Muse cells, either endogenous or administered exogenously, selectively ...
Source: Frontiers in Pharmacology - October 19, 2022 Category: Drugs & Pharmacology Source Type: research
Neurological consequences of COVID-19
Pharmacol Rep. 2022 Sep 30. doi: 10.1007/s43440-022-00424-6. Online ahead of print.ABSTRACTIn December 2019, cases of pneumonia caused by infection with the previously unknown severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), leading to coronavirus disease 2019 (COVID-19), were identified. Typical manifestations of COVID-19 are fever, cough, fatigue and dyspnoea. Initially, it was thought that the mechanism of action of SARS-CoV-2 was only associated with respiratory tract invasion, but it was later revealed that the infection might involve many other organs and systems, including the central and peripheral ner...
Source: Pharmacological Reports - September 30, 2022 Category: Drugs & Pharmacology Authors: Waldemar Brola Maciej Wilski Source Type: research
Efficacy and Safety of Shenfu Injection for Severe Pneumonia in the Elderly: A Systematic Review and Meta-Analysis Based on Western and Eastern Medicine
Conclusion: SFI as an adjuvant may improve the total effective rate, APACHE II score, gas exchange, and predictors associated with COVID-19 progression, reducing mortality and safety concerns for elderly patients with severe pneumonia.PMID:36091817 | PMC:PMC9454296 | DOI:10.3389/fphar.2022.779942
Source: Pharmacological Reviews - September 12, 2022 Category: Drugs & Pharmacology Authors: Shihua Shi Fei Wang Bonan Chen Jie Pan Dan Luo Caixia Pei Demei Huang Xiaomin Wang Yilan Wang Zherui Shen Weihao Li Yongcan Wu Yacong He Zhenxing Wang Source Type: research
Cerebrovascular radiological features of COVID-19 positive patients
CONCLUSIONS: Cerebrovascular diseases, which may cause severe disability and even threaten the patient's life, should be kept in mind, especially in COVID-19 patients who present with neurological symptoms.PMID:36066171 | DOI:10.26355/eurrev_202208_29535
Source: European Review for Medical and Pharmacological Sciences - September 6, 2022 Category: Drugs & Pharmacology Authors: B Petik M Akcicek M Sahin N Dag Source Type: research
